KIT and lung cancer: Oncogenic KIT shuttled in EVs may impact the pathogenesis of diseases (Atay et al., 2014; Kim et al., 2018; Kim et al., 2021), or reflect disease status as implied in studies of EGFR‐containing EVs in lung cancer or other malignancies (Bijnsdorp et al., 2021; Frawley & Piskareva, 2020; Purcell et al., 2021).